A randomized controlled trial comparing repeat doses of 400 mcg sublingual to buccal misoprostol after mifepristone for termination of pregnancy 13–21 weeks

Medical regimens for abortion at 12 weeks and above: a systematic review and meta-analysis

“…7 , Supplements 8C and 9C) [ 21 , 40 ]. One trial ( N = 50) compared vaginal vs. buccal routes of misoprostol (Appendix 6D, Supplement 3 D) [ 41 ]. Another trial ( N = 339) compared sublingual vs. buccal routes of misoprostol (Appendix 6E, Supplement 3 E) [ 42 ].…”

“…Across all included studies, authors reported 106 SAEs. Ten studies did not supply data on SAEs [ 22 , 26 , 27 , 30 , 31 , 41 , 44 , 49 , 54 , 56 ]. In removing the population of women from the 10 studies not reporting SAEs, we calculated an overall SAE rate of 1.7% (106/6313).…”

“…The WHO used the results of this review to directly inform its recent Medical management of abortion guidance [ 11 ]. Our review builds on the 2011 Cochrane review [ 5 ] of second-trimester medical abortion methods by evaluating 26 new trials [ [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] , [55] ]. Based on our analysis, we recommend a regimen of mifepristone 200 mg 1 to 2 days before misoprostol 400 mcg every 3 h via vaginal, sublingual or buccal routes.…”